Research at the Insitute for Medical Virology under the direction of Karin Moelling established various approaches for intervention against infectious diseases, cancer or Alzheimer’s disease. DBM Dahlem Biomed AG is a registered company founded by Karin Moelling (for contact see home). The profile of the company is presently consulting in Biotechnology, Biomedicine, Biology with focus on drug and vaccine design and developent, company profiles, clinical trials, reaching all the way from laboratory bench to patient bedside.

A selection of the projects described below may be developed in collaboration with DBM Dahlem Biomed AG in the near future depending on fundrising and partnerships.

Karin Moelling welcomes requests from potential partners who are interested in working with her business ideas. If you are interested in discussing the possibility of a partnership please contact Karin Moelling. Please note that GMP material for project 2 is available for partnering.

Currently, five business ideas exist, which are described here.

  1. Gene silencing as antiviral and anticancer treatment -> Genesilencing
  2. Immune therapy against cancer by gene medicine -> Immune therapy
  3. Treatment of Age-related Macular Degeneration -> AMD
  4. New target against Diabetes -> Diabetes
  5. Therapy of Alzheimers Disease (AD) -> Alzheimer`s disease

Several patents owned by the Unitectra Zurich, the technology transfer organization of the University of Zurich, are filed or issued.

Business plans and confidential information are available upon request and CDA
Prof. Dr. Karin Moelling will be available for consulting in scientific as well as in company development issues. She has experience in two clinical trials, two compassionate trials (in Zurich and at the Charité in Berlin), and a clinical trial in Zurich – the first plasmid DNA trial in Europe. She was part-time employee of a Biotech Company in the USA (Apollon) as CSO for a plasmid DNA vaccine against HIV, including pre-IND meeting at NIH, patenting and regulatory affairs. She is co-founder of three biotech companies and was member of the governmental program BioRegio (initiated by former Research Minister Dr. Jürgen Rüttgers and Chancellor Dr. Helmut Kohl) and the Technologie and Innovations Rat (TIR) of the City of Berlin. She is author of about 230 peer-reviewed publications in scientific journals and currently works in Berlin at the Max-Planck-Institute for Molecular Genetics, where laboratory facilities and infrastructure are available, as well as at the University of Zurich.
Presentation: Silencing of RNA in Viruses and Cancer by „siDNA“ – Powerpoint siDNA 2010.pdf

Most important papers for immediate reading

Matzen, K., Elzaouk, L., Matskevich A.A., Nitzsche, A., Heinrich, J. and Moelling, K. RNase H-mediated retrovirus destruction in vivo triggered by oligodeoxynucleotides. Nature Biotechnol. 25, 669-674 (2007). – Matzen 2007.pdf

Editorial Comment: Assisted suicide for retroviruses Nature Biotechnol. 25,643-644(2007)

For further publications please go to Research__Therascope